The Motley Fool·2026-02-11 06:15Core Insights - The article discusses the potential of Viking Therapeutics (VKTX) as a contender in the GLP-1 drug market, which is currently dominated by Eli Lilly and Novo Nordisk [1][2][3] Industry Overview - GLP-1 drugs have gained popularity for their effectiveness in weight loss, leading to significant sales for current market leaders [1][5] - There is increasing competition in the GLP-1 market, with other pharmaceutical and biotech companies developing their own candidates [2][6] Company Analysis - Viking Therapeutics is currently studying VK2735, which is in phase 3 trials for an injectable formulation and phase 2 for a pill format, showing promising clinical trial results [6][10] - The dual formulation of VK2735 allows for easy switching between injectable and oral forms, enhancing patient convenience [7] - Viking's stock has historically reacted positively to good news, with a notable 121% increase following positive phase 2 trial data two years ago [9][10] Financial Metrics - Viking Therapeutics has a current market capitalization of $3.2 billion, with a stock price of $28.75 [9] - The stock has a 52-week range of $18.92 to $43.15, indicating volatility and potential for growth [9] Future Outlook - Positive trial results and potential regulatory approval for VK2735 could lead to significant revenue growth and profit for Viking [10] - There are suggestions that Viking could be a takeover target, which may provide additional investment opportunities [10]